The continued expansion of GLP-1 weight-loss therapies has introduced both commercial opportunity and evolving legal and regulatory considerations across the health care landscape. Novo Nordisk’s (“Novo”) recent federal lawsuit against Hims & Hers (“Hims”) illustrates how brand manufacturers may increasingly use patent and regulatory frameworks to challenge the marketing and sale of compounded versions... READ MORE
GLP-1 Gold Rush Meets Legal Reality: Novo Nordisk Challenges Compounded Alternatives
Posted on March 5, 2026 in Health Law News
Published by: Hall Render
